AnPac Bio Announces Appointment of New Chief Financial Officer
SAN JOSE, Calif., June 02, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”)
Read moreApproval
Global Dry Eye Medication Market Opportunities and Strategies (2019 to 2030) – COVID-19 Impact and Recovery
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Medication Global Market Opportunities and Strategies to 2030: COVID 19 Impact and Recovery” report has been
Read more
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
Read more
ProMIS offeri potential significant advantage over aducanumab, learns from mistakes
ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.
Read more
Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.
Read more
Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)
Read more
CB Therapeutics Secures new Research and Production Facility
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its
Read more
Vaxart Announces Closing of Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather
Read more
First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute
STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient
Read moreTransgene: A Positive 2018, Moving Ahead with a Strong Portfolio
2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver
Read more